We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00018642
First Posted: July 5, 2001
Last Update Posted: January 21, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
VA Office of Research and Development
July 3, 2001
July 5, 2001
January 21, 2009
April 1997
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00018642 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia
The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
  • Schizophrenia
  • Schizoaffective Disorder
  • Drug: quetiapine
  • Drug: haloperidol decanoate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
March 2002
Not Provided

Inclusion Criteria

  1. Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV
  2. Between the ages 18-60.
  3. A candidate for maintenance antipsychotic therapy. This means that patients will have had at least two documented episodes of acute schizophrenic illness or at least two years of continuing psychotic symptoms.

Exclusion Criteria

  1. Organic brain disease.
  2. Mental Retardation
  3. Chronic medical illness which would make antipsychotic medication inappropriate.
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00018642
MHBS-042-96F
Not Provided
Not Provided
Not Provided
Not Provided
VA Office of Research and Development
Not Provided
Not Provided
VA Office of Research and Development
December 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP